These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

210 related items for PubMed ID: 20404564

  • 1. The effects of the histone deacetylase inhibitor romidepsin (FK228) are enhanced by aspirin (ASA) in COX-1 positive ovarian cancer cells through augmentation of p21.
    Son DS, Wilson AJ, Parl AK, Khabele D.
    Cancer Biol Ther; 2010 Jun 01; 9(11):928-35. PubMed ID: 20404564
    [Abstract] [Full Text] [Related]

  • 2. Histone deacetylase inhibitor, Romidepsin (FK228) inhibits endometrial cancer cell growth through augmentation of p53-p21 pathway.
    Li LH, Zhang PR, Cai PY, Li ZC.
    Biomed Pharmacother; 2016 Aug 01; 82():161-6. PubMed ID: 27470351
    [Abstract] [Full Text] [Related]

  • 3. Romidepsin (FK228) and its analogs directly inhibit phosphatidylinositol 3-kinase activity and potently induce apoptosis as histone deacetylase/phosphatidylinositol 3-kinase dual inhibitors.
    Saijo K, Katoh T, Shimodaira H, Oda A, Takahashi O, Ishioka C.
    Cancer Sci; 2012 Nov 01; 103(11):1994-2001. PubMed ID: 22924958
    [Abstract] [Full Text] [Related]

  • 4. Biochemical, biological and structural properties of romidepsin (FK228) and its analogs as novel HDAC/PI3K dual inhibitors.
    Saijo K, Imamura J, Narita K, Oda A, Shimodaira H, Katoh T, Ishioka C.
    Cancer Sci; 2015 Feb 01; 106(2):208-15. PubMed ID: 25492515
    [Abstract] [Full Text] [Related]

  • 5. Pharmacological or transcriptional inhibition of both HDAC1 and 2 leads to cell cycle blockage and apoptosis via p21Waf1/Cip1 and p19INK4d upregulation in hepatocellular carcinoma.
    Zhou H, Cai Y, Liu D, Li M, Sha Y, Zhang W, Wang K, Gong J, Tang N, Huang A, Xia J.
    Cell Prolif; 2018 Jun 01; 51(3):e12447. PubMed ID: 29484736
    [Abstract] [Full Text] [Related]

  • 6. Histone deacetylase inhibitor FK228 activates tumor suppressor Prdx1 with apoptosis induction in esophageal cancer cells.
    Hoshino I, Matsubara H, Hanari N, Mori M, Nishimori T, Yoneyama Y, Akutsu Y, Sakata H, Matsushita K, Seki N, Ochiai T.
    Clin Cancer Res; 2005 Nov 01; 11(21):7945-52. PubMed ID: 16278420
    [Abstract] [Full Text] [Related]

  • 7. Inhibition of class I histone deacetylases by romidepsin potently induces Epstein-Barr virus lytic cycle and mediates enhanced cell death with ganciclovir.
    Hui KF, Cheung AK, Choi CK, Yeung PL, Middeldorp JM, Lung ML, Tsao SW, Chiang AK.
    Int J Cancer; 2016 Jan 01; 138(1):125-36. PubMed ID: 26205347
    [Abstract] [Full Text] [Related]

  • 8. Romidepsin (depsipeptide) induced cell cycle arrest, apoptosis and histone hyperacetylation in lung carcinoma cells (A549) are associated with increase in p21 and hypophosphorylated retinoblastoma proteins expression.
    Vinodhkumar R, Song YS, Devaki T.
    Biomed Pharmacother; 2008 Feb 01; 62(2):85-93. PubMed ID: 17644301
    [Abstract] [Full Text] [Related]

  • 9. Histone deacetylase inhibitor suppression of autoantibody-mediated arthritis in mice via regulation of p16INK4a and p21(WAF1/Cip1) expression.
    Nishida K, Komiyama T, Miyazawa S, Shen ZN, Furumatsu T, Doi H, Yoshida A, Yamana J, Yamamura M, Ninomiya Y, Inoue H, Asahara H.
    Arthritis Rheum; 2004 Oct 01; 50(10):3365-76. PubMed ID: 15476220
    [Abstract] [Full Text] [Related]

  • 10. Romidepsin (FK228), A Histone Deacetylase Inhibitor and its Analogues in Cancer Chemotherapy.
    Pojani E, Barlocco D.
    Curr Med Chem; 2021 Oct 01; 28(7):1290-1303. PubMed ID: 32013816
    [Abstract] [Full Text] [Related]

  • 11. The use of histone deacetylase inhibitor FK228 and DNA hypomethylation agent 5-azacytidine in human bladder cancer therapy.
    Karam JA, Fan J, Stanfield J, Richer E, Benaim EA, Frenkel E, Antich P, Sagalowsky AI, Mason RP, Hsieh JT.
    Int J Cancer; 2007 Apr 15; 120(8):1795-802. PubMed ID: 17230511
    [Abstract] [Full Text] [Related]

  • 12. Drug-induced inactivation or gene silencing of class I histone deacetylases suppresses ovarian cancer cell growth: implications for therapy.
    Khabele D, Son DS, Parl AK, Goldberg GL, Augenlicht LH, Mariadason JM, Rice VM.
    Cancer Biol Ther; 2007 May 15; 6(5):795-801. PubMed ID: 17387270
    [Abstract] [Full Text] [Related]

  • 13. Changes in histone deacetylase (HDAC) expression patterns and activity of HDAC inhibitors in urothelial cancers.
    Niegisch G, Knievel J, Koch A, Hader C, Fischer U, Albers P, Schulz WA.
    Urol Oncol; 2013 Nov 15; 31(8):1770-9. PubMed ID: 22944197
    [Abstract] [Full Text] [Related]

  • 14. Histone deacetylase inhibitor depsipeptide (FK228) induces apoptosis in leukemic cells by facilitating mitochondrial translocation of Bax, which is enhanced by the proteasome inhibitor bortezomib.
    Sutheesophon K, Kobayashi Y, Takatoku MA, Ozawa K, Kano Y, Ishii H, Furukawa Y.
    Acta Haematol; 2006 Nov 15; 115(1-2):78-90. PubMed ID: 16424655
    [Abstract] [Full Text] [Related]

  • 15. Additive inhibition of colorectal cancer cell lines by aspirin and bortezomib.
    Voutsadakis IA, Patrikidou A, Tsapakidis K, Karagiannaki A, Hatzidaki E, Stathakis NE, Papandreou CN.
    Int J Colorectal Dis; 2010 Jul 15; 25(7):795-804. PubMed ID: 20397022
    [Abstract] [Full Text] [Related]

  • 16. Synergistic efficacy in human ovarian cancer cells by histone deacetylase inhibitor TSA and proteasome inhibitor PS-341.
    Fang Y, Hu Y, Wu P, Wang B, Tian Y, Xia X, Zhang Q, Chen T, Jiang X, Ma Q, Xu G, Wang S, Zhou J, Ma D, Meng L.
    Cancer Invest; 2011 May 15; 29(4):247-52. PubMed ID: 21345073
    [Abstract] [Full Text] [Related]

  • 17. Antitumor activity and pharmacologic characterization of the depsipeptide analog as a novel histone deacetylase/ phosphatidylinositol 3-kinase dual inhibitor.
    Saijo K, Imai H, Chikamatsu S, Narita K, Katoh T, Ishioka C.
    Cancer Sci; 2017 Jul 15; 108(7):1469-1475. PubMed ID: 28406576
    [Abstract] [Full Text] [Related]

  • 18. Anticolon cancer activity of largazole, a marine-derived tunable histone deacetylase inhibitor.
    Liu Y, Salvador LA, Byeon S, Ying Y, Kwan JC, Law BK, Hong J, Luesch H.
    J Pharmacol Exp Ther; 2010 Nov 15; 335(2):351-61. PubMed ID: 20739454
    [Abstract] [Full Text] [Related]

  • 19. Synergistic effect of histone deacetylase inhibitors FK228 and m-carboxycinnamic acid bis-hydroxamide with proteasome inhibitors PSI and PS-341 against gastrointestinal adenocarcinoma cells.
    Adachi M, Zhang Y, Zhao X, Minami T, Kawamura R, Hinoda Y, Imai K.
    Clin Cancer Res; 2004 Jun 01; 10(11):3853-62. PubMed ID: 15173094
    [Abstract] [Full Text] [Related]

  • 20. Romidepsin (FK228), a potent histone deacetylase inhibitor, induces apoptosis through the generation of hydrogen peroxide.
    Mizutani H, Hiraku Y, Tada-Oikawa S, Murata M, Ikemura K, Iwamoto T, Kagawa Y, Okuda M, Kawanishi S.
    Cancer Sci; 2010 Oct 01; 101(10):2214-9. PubMed ID: 20624163
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.